ArticleJournal of hematology & oncology2022
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials.
Article in Journal of hematology & oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort.Annals of oncology : official journal of the European Society for Medical Oncology · 2026Guideline
- Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial.Cancer discovery · 2023Trial
- Trials for Rare Cancers Are More Successful than those for Common Cancers.ESMO rare cancers · 2026Article
- Success rates of American clinical oncology trials by geographic factors.Scientific reports · 2026Article
- A comprehensive analysis of dry eye disease clinical trials (2000-2024): research trends and gaps.Frontiers in pharmacology · 2026Article
- Peripheral eosinophils and immunotherapy response in patients with recurrent or metastatic HNSCC.Scientific reports · 2025Article
- Advancements in Melanoma Treatment: A Review of PD-1 Inhibitors, T-VEC, mRNA Vaccines, and Tumor-Infiltrating Lymphocyte Therapy in an Evolving Landscape of Immunotherapy.Journal of clinical medicine · 2025Review
- Blockade of CCR5Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Trends in Israeli clinical trials registration "MyTrial".Israel journal of health policy research · 2024Article
- Efficacy and Safety of Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Antibodies Plus Chemotherapy as First-Line Treatment for NSCLC in the People's Republic of China: a Systematic Review and Meta-Analysis.JTO clinical and research reports · 2024Article
- Outcome differences by sex in oncology clinical trials.Nature communications · 2024Article
- Clinical development of mRNA therapies against solid tumors.Journal of hematology & oncology · 2023Article
- Supramolecular Biomaterials for Cancer Immunotherapy.Research (Washington, D.C.) · 2023Review
- Characterization of Oncology Clinical Trials Using Germline Genetic Data.JAMA network open · 2022Article
- [Progress and Application of Bayesian Approach in the Early Research and Development of New Anticancer Drugs].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Article
- Availability and Affordability of Oncology Drugs in 2012-2021 in China and the United States.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The neoadjuvant and adjuvant anti-PD-1/PD-L1 treatment has been increasingly noticed. To summarize the global landscape of these clinical trials will provide essential data for all the stakeholders of drug development. Based on the Trialtrove database, a total of 668 clinical trials initiated by the end of 2020 were retrospectively analyzed. We found that a rising capability of global neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical development has been achieved. High prevalent cancer types were extensively studied though the priorities in China and the United States were different. However, a lack of phase III trials and industry-sponsored trials was addressed. The confirmatory neoadjuvant trials were particularly insufficient, and the combination strategy mainly focused on chemotherapy. Thus, more public funding and accelerated regulatory strategies are needed in this field. Efforts should be made to confirm the benefit of neoadjuvant treatment and explore novel combination strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.